DK0626387T3 - Nukleosider og oligonukleotider med 2'-ethergrupper - Google Patents

Nukleosider og oligonukleotider med 2'-ethergrupper

Info

Publication number: DK0626387T3
Authority: DK; Denmark
Prior art keywords: alkyl; hydrogen; formula; radical; nucleosides
Prior art date: 1993-05-12

Application number

DK94810255T

Other languages

English (en)

Inventor

Pierre Dr Martin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-12

Filing date

1994-05-03

Publication date

1999-09-27

1994-05-03 Application filed by Novartis Ag filed Critical Novartis Ag

1999-09-27 Application granted granted Critical

1999-09-27 Publication of DK0626387T3 publication Critical patent/DK0626387T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
239000002777 nucleoside Substances 0.000 title 1
125000003835 nucleoside group Chemical group 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical group 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
229910052698 phosphorus Inorganic materials 0.000 abstract 1
239000011574 phosphorus Substances 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK94810255T 1993-05-12 1994-05-03 Nukleosider og oligonukleotider med 2'-ethergrupper DK0626387T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH146793		1993-05-12

Publications (1)

Publication Number	Publication Date
DK0626387T3 true DK0626387T3 (da)	1999-09-27

Family

ID=4211171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94810255T DK0626387T3 (da)	1993-05-12	1994-05-03	Nukleosider og oligonukleotider med 2'-ethergrupper

Country Status (11)

Country	Link
US (1)	US5969116A (da)
EP (1)	EP0626387B1 (da)
JP (1)	JP4012579B2 (da)
CN (1)	CN1100728A (da)
AT (1)	ATE177430T1 (da)
AU (1)	AU687796B2 (da)
CA (1)	CA2123241C (da)
DE (1)	DE59407895D1 (da)
DK (1)	DK0626387T3 (da)
ES (1)	ES2128535T3 (da)
IL (3)	IL123330A (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789573A (en) *	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
ATE244723T1 (de) *	1994-04-27	2003-07-15	Novartis Pharma Gmbh	Nukleoside und oligonukleotide mit 2'- ethergruppen
WO1996027606A1 (en)	1995-03-06	1996-09-12	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) *	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US20110028350A1 (en) *	1995-12-15	2011-02-03	Affymetrix, Inc.	Photocleavable protecting groups
US6147205A (en) *	1995-12-15	2000-11-14	Affymetrix, Inc.	Photocleavable protecting groups and methods for their use
DE69729179T2 (de) *	1996-02-14	2004-12-30	Isis Pharmaceuticals, Inc., Carlsbad	Lückenhaft Zucker-modifizierte Oligonukleotide
AU3029797A (en)	1996-06-06	1998-01-05	Novartis Ag	2'-substituted nucleosides and oligonucleotide derivatives
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
EP0979309A4 (en) *	1997-04-30	2000-10-18	Isis Pharmaceuticals Inc	Oligonucleotides for enhanced bioavailability
US20040063618A1 (en) *	2002-09-30	2004-04-01	Muthiah Manoharan	Peptide nucleic acids having improved uptake and tissue distribution
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US6093807A (en) *	1999-03-19	2000-07-25	Isis Pharmaceuticals, Inc.	Sugar-modified 7-deaza-7-substituted oligonucleotides
EP1325017A2 (en) *	2000-09-11	2003-07-09	Affymetrix, Inc.	Photocleavable protecting groups
US20030027169A1 (en) *	2000-10-27	2003-02-06	Sheng Zhang	One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
AU2003290598A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) *	2004-11-16	2007-11-20	Hwang David L	Chromium complex with insulin-like activity
US7547775B2 (en) *	2004-12-31	2009-06-16	Affymetrix, Inc.	Parallel preparation of high fidelity probes in an array format
US8338093B2 (en) *	2004-12-31	2012-12-25	Affymetrix, Inc.	Primer array synthesis and validation
NZ562954A (en)	2005-05-05	2009-10-30	Antisense Pharma Gmbh	Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
AU2007265434B2 (en)	2006-06-28	2012-08-02	Cibus Europe B.V.	Fatty acid blends and uses therefor
US7820810B2 (en)	2007-03-19	2010-10-26	Isis Pharmaceuticals, Inc.	Process for the synthesis of 2′-O-substituted purine nulceosides
WO2009067243A2 (en)	2007-11-20	2009-05-28	Isis Pharmaceuticals Inc.	Modulation of cd40 expression
WO2009068617A1 (en)	2007-11-30	2009-06-04	Boehringer Ingelheim International Gmbh	1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
CN102016036B (zh)	2008-02-11	2015-04-08	阿克赛医药公司	经修饰的RNAi多核苷酸及其用途
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
JP5453431B2 (ja)	2008-09-08	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
WO2010033247A2 (en)	2008-09-22	2010-03-25	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
EP2358397B1 (en)	2008-10-24	2020-01-01	Ionis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CA2753975C (en) *	2009-03-02	2017-09-26	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
BRPI1011533A2 (pt)	2009-03-31	2016-03-29	Boehringer Ingelheim Int	derivados de 1-heterocicil-1 5- diidro-pirazolo [3,4--d] pirimidin-4-ona e seu uso como moduladores de pde9a.
AR077859A1 (es) *	2009-08-12	2011-09-28	Boehringer Ingelheim Int	Compuestos para el tratamiento de trastornos del snc
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
CN106074591B (zh)	2010-03-24	2020-01-14	菲奥医药公司	眼部症候中的rna干扰
AU2011232365A1 (en)	2010-03-24	2012-10-25	Rxi Pharmaceuticals Corporation	RNA interference in dermal and fibrotic indications
EP3091027B1 (en)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
CN103154014B (zh)	2010-04-28	2015-03-25	Isis制药公司	修饰核苷、其类似物以及由它们制备的寡聚化合物
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
JP5756176B2 (ja)	2010-08-12	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	６−シクロアルキル−１，５−ジヒドロ−ピラゾロ（３，４−ｄ）ピリミジ−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用
EP2453017A1 (en)	2010-11-12	2012-05-16	Antisense Pharma GmbH	Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) *	2011-09-19	2016-02-10	上海兆维科技发展有限公司	2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
US9920319B2 (en)	2013-05-03	2018-03-20	Council Of Scientific & Industrial Research	2′/3′/5′-(R/S)-serinyl functionalized oligonucleotides
EP3564374A1 (en)	2013-06-21	2019-11-06	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
WO2015084897A2 (en)	2013-12-02	2015-06-11	Mirimmune, Llc	Immunotherapy of cancer
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
EP3188799B1 (en)	2014-09-05	2022-07-06	Phio Pharmaceuticals Corp.	Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
WO2017007813A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA3002744A1 (en)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
JP6853537B2 (ja)	2016-02-17	2021-03-31	国立大学法人東京工業大学	人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
KR102724871B1 (ko) *	2017-08-18	2024-10-31	애질런트 테크놀로지스, 인크.	올리고뉴클레오티드의 친화성 정제를 위한 오르토에스터 조성물
AU2019207703B2 (en)	2018-01-09	2024-11-14	Cibus Europe B.V.	Shatterproof genes and mutations
MX2020009765A (es)	2018-03-20	2021-01-08	Tokyo Inst Tech	Oligonucleotido antisentido reducido en toxicidad.
KR20240050303A (ko)	2021-08-24	2024-04-18	닛산 가가쿠 가부시키가이샤	2’ 수식 구아노신 화합물의 제조방법
KR20240072136A (ko)	2021-09-30	2024-05-23	닛산 가가쿠 가부시키가이샤	2’수식 피리미딘뉴클레오시드의 제조방법
CN116606336B (zh) *	2022-04-02	2025-09-12	思合基因(北京)生物科技有限公司	高稳定性和亲和力的2′-o-取代核苷及其应用
WO2025005265A1 (ja) *	2023-06-30	2025-01-02	日産化学株式会社	毒性が低減されたアンチセンスオリゴヌクレオチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) *	1986-10-28	1990-09-19	The Johns Hopkins University	Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
WO1989008146A1 (en) *	1988-02-26	1989-09-08	Worcester Foundation For Experimental Biology	Inhibition of htlv-iii by exogenous oligonucleotides
JPH05504552A (ja) *	1989-10-24	1993-07-15	ギリアド　サイエンシズ，インコーポレイテッド	２’位が改変されたオリゴヌクレオチド
HUT63170A (en) *	1990-01-11	1993-07-28	Isis Pharmaceuticals Inc	Process and composition for detecting and modifying rna activity and gene expression
US5212295A (en) *	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
CA2089376C (en) *	1990-08-13	2010-05-04	Phillip Dan Cook	Sugar modified oligonucleotides that detect and modulate gene expression
CA2126691C (en) *	1991-12-24	2003-05-06	Phillip Dan Cook	Gapped 2' modified oligonucleotides
CA2140428C (en) *	1992-07-23	2003-07-08	Daniel Peter Claude Mcgee	Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

1994
- 1994-05-03 DK DK94810255T patent/DK0626387T3/da active
- 1994-05-03 AT AT94810255T patent/ATE177430T1/de active
- 1994-05-03 DE DE59407895T patent/DE59407895D1/de not_active Expired - Lifetime
- 1994-05-03 EP EP94810255A patent/EP0626387B1/de not_active Expired - Lifetime
- 1994-05-03 ES ES94810255T patent/ES2128535T3/es not_active Expired - Lifetime
- 1994-05-10 IL IL12333094A patent/IL123330A/xx not_active IP Right Cessation
- 1994-05-10 CA CA002123241A patent/CA2123241C/en not_active Expired - Lifetime
- 1994-05-10 IL IL10960594A patent/IL109605A/xx not_active IP Right Cessation
- 1994-05-11 CN CN94105715A patent/CN1100728A/zh active Pending
- 1994-05-11 AU AU63044/94A patent/AU687796B2/en not_active Expired
- 1994-05-12 JP JP12295794A patent/JP4012579B2/ja not_active Expired - Lifetime
1995
- 1995-06-02 US US08/459,434 patent/US5969116A/en not_active Expired - Fee Related
1998
- 1998-02-17 IL IL12333098A patent/IL123330A0/xx unknown

Also Published As

Publication number	Publication date
CA2123241C (en)	2007-02-13
JPH072889A (ja)	1995-01-06
IL123330A (en)	1999-12-31
CA2123241A1 (en)	1994-11-13
IL109605A (en)	1999-12-31
CN1100728A (zh)	1995-03-29
JP4012579B2 (ja)	2007-11-21
AU687796B2 (en)	1998-03-05
EP0626387B1 (de)	1999-03-10
IL123330A0 (en)	1998-09-24
AU6304494A (en)	1994-11-17
ES2128535T3 (es)	1999-05-16
DE59407895D1 (de)	1999-04-15
ATE177430T1 (de)	1999-03-15
US5969116A (en)	1999-10-19
EP0626387A1 (de)	1994-11-30
IL109605A0 (en)	1994-08-26

Publication	Publication Date	Title
DK0626387T3 (da)	1999-09-27	Nukleosider og oligonukleotider med 2'-ethergrupper
BG95575A (bg)	1993-12-24	3'-(2')-амино-и тиолмодифицирани, свързани с флуоресциращо багрило нуклеозиди,нуклеотиди и олигонуклеотиди и метод за тяхното получаване и приложението им
DE69815342D1 (de)	2003-07-10	Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
NO303543B1 (no)	1998-07-27	Nukleosid-5'-trifosfat og fosforamiditt samt anvendelser derav
DE3751947D1 (de)	1996-12-12	Nucleosidderivate und ihre Verwendung in der Oligonucleotid-Synthese
FI104176B1 (fi)	1999-11-30	Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
DE3670293D1 (de)	1990-05-17	Adenosin-nukleosid-derivate, ihre herstellung und biologische verwendung.
ES2106684A1 (es)	1997-11-01	2-hidroxifeniltriazinas.
DK0679657T3 (da)	2003-10-27	Nukleosider og oligonukleotider med 2'-ethergrupper
MX166257B (es)	1992-12-24	Composicion de revestimiento que contiene grupos de carbamato de hidroxialquilo
ATE179983T1 (de)	1999-05-15	Antiretrovirale, enantiomere nukleotid-analoge
ATE167679T1 (de)	1998-07-15	Wirkstoffvorläufer von phosphonaten
WO2002014439A3 (en)	2002-06-13	Process for producing coatings using surface-active photoinitiators
MX214967B (es)	2003-06-26	Morfolinas como estabilizantes de luz
DK0816368T3 (da)	2003-05-05	Kemisk phosphorylering af oligonukleotider og reaktanter anvendt dertil
FI923170A0 (fi)	1992-07-09	Spicamycinderivat och anvaendning av dem.
DE69621229D1 (de)	2002-06-20	Antivirale triazazyklododecane
CA2042745A1 (en)	1991-11-19	Novel hardenable compositions
TW334451B (en)	1998-06-21	Composition which can be crosslinked by light
HUT45541A (en)	1988-07-28	Plant protecting compositions containing ester of phosphoric acid as active component and process for producing the active component
IE812876L (en)	1982-06-09	Ethers of substituted hydroxymethylpyrazines
WO1994009011A1 (de)	1994-04-28	Quartäre ammoniumgruppen enthaltende siloxanderivate, verfahren zu ihrer herstellung und ihre verwendung
GR3019075T3 (en)	1996-05-31	Inhibitor of herpes simplex viral thymidine kinase
IL90972A0 (en)	1990-02-09	Process for the preparation of halosilanes
TH13566A (th)	1993-12-15	พิริดิโน-, พิร์โรลิดิโน-และแอ ซิพิโน-ซับสทิทิวเทด ออกซีมออกซีมซึ่ง มีประโยชน์เป็นสารต่อต้านอาเธอ โรสเคลอโร